The
drug, bermekimab, is a human monoclonal antibody that was being
tested for the treatment of chronic skin diseases atopic dermatitis
and hidradenitis suppurativa.
J&J said it had decided to terminate the development of the drug for
atopic dermatitis following the availability of additional efficacy
data.
The company had struck a $750 million deal in late 2019 to purchase
all rights to the drug, which was in Phase 2 development, from
XBiotech Inc.
![](http://archives.lincolndailynews.com/2016/Aug/26/images/ads/current/ldn_sda_062409.png)
J&J said bermekimab will retain a carrying value of about $150
million relating to hidradenitis suppurativa, after the impairment
charge.
[to top of second column] |
![](http://archives.lincolndailynews.com/2022/Feb/03/images/ads/current/chicagost_lda_LUAL_2021.png)
Atopic dermatitis, commonly known as eczema, is characterized by
skin inflammation and redness. Hidradenitis suppurativa causes
painful lumps to form under the skin, especially in areas such as
armpits where the skin rubs together.
(Reporting by Amruta Khandekar; Editing by Anil D'Silva)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |